The outcomes of using colistin for treating multidrug resistant Acinetobacter species bloodstream infections

Journal of Korean Medical Science

Volumn 26, Issue 3, 2011, Pages 325-331

  Lim, Seung Kwan ^a   Lee, Sang Oh ^b   Choi, Seong Ho ^c   Choi, Jae Phil ^d   Kim, Sung Han ^b   Jeong, Jin Yong ^b   Choi, Sang Ho ^b   Woo, Jun Hee ^b   Kim, Yang Soo ^b  

^a Ajou University School of Medicine   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c Chung Ang University College of Medicine   (South Korea)

^d Seoul Medical Center   (South Korea)

Author keywords

Acinetobacter; Bacteremia; Colistin; Drug resistance; Multiple

Indexed keywords

ANTIINFECTIVE AGENT; COLISTIN;

ACINETOBACTER; ACINETOBACTER INFECTION; ADOLESCENT; ADULT; AGED; APACHE; ARTICLE; BACTEREMIA; CHILD; DRUG EFFECT; FEMALE; HUMAN; ISOLATION AND PURIFICATION; MALE; MIDDLE AGED; MORTALITY; MULTIDRUG RESISTANCE; RETROSPECTIVE STUDY; RISK; SOUTH KOREA; TREATMENT OUTCOME;

ACINETOBACTER; ACINETOBACTER INFECTIONS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; APACHE; BACTEREMIA; CHILD; COLISTIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; RISK; TREATMENT OUTCOME;

EID: 79953744733     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2011.26.3.325     Document Type: Article

References (30)

1. Hsueh PR, Teng LJ, Chen CY, Chen WH, Yu CJ, Ho SW, Luh KT. Pandrug-resistant Acinetobacter baumannii causing nosocomial infections in a university hospital, Taiwan. Emerg Infect Dis 2002; 8: 827-32.
2. Mera RM, Miller LA, Amrine-Madsen H, Sahm DF. Acinetobacter baumannii 2002-2008: increase of carbapenem-associated multiclass resistance in the United States. Microb Drug Resist 2010; 16: 209-15.
3. Choi WS, Kim SH, Jeon EG, Son MH, Yoon YK, Kim JY, Kim MJ, Sohn JW, Park DW. Nosocomial outbreak of carbapenem-resistant Acinetobacter baumannii in intensive care units and successful outbreak control program. J Korean Med Sci 2010; 25: 999-1004.
4. Falagas ME, Kasiakou SK, Tsiodras S, Michalopoulos A. The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature. Clin Med Res 2006; 4: 138-46.
5. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 2005; 40: 1333-41.
6. Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, Paterson DL. Colistin: the re-emerging antibiotic for multidrug-resistant Gramnegative bacterial infections. Lancet Infect Dis 2006; 6: 589-601.
7. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008; 36: 309-32.
8. Kasiakou SK, Michalopoulos A, Soteriades ES, Samonis G, Sermaides GJ, Falagas ME. Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Antimicrob Agents Chemother 2005; 49: 3136-46.
9. CLSI. Performance standards for antimicrobial susceptability testing, 16th informational supplement, M100-S16. Wayne, PA: Clinical and Laboratory Standards Institute; 2006.
10. Zimmerman JE, Knaus WA, Sun X, Wagner DP. Severity stratification and outcome prediction for multisystem organ failure and dysfunction. World J Surg 1996; 20: 401-5.
11. Lautenbach E, Synnestvedt M, Weiner MG, Bilker WB, Vo L, Schein J, Kim M. Epidemiology and impact of imipenem resistance in Acinetobacter baumannii. Infect Control Hosp Epidemiol 2009; 30: 1186-92.
12. Michalopoulos AS, Tsiodras S, Rellos K, Mentzelopoulos S, Falagas ME. Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old antibiotic. Clin Microbiol Infect 2005; 11: 115-21.
13. Falagas ME, Bliziotis IA, Siempos II. Attributable mortality of Acinetobacter baumannii infections in critically ill patients: a systematic review of matched cohort and case-control studies. Crit Care 2006; 10: R48.
14. Joly-Guillou ML. Clinical impact and pathogenicity of Acinetobacter. Clin Microbiol Infect 2005; 11: 868-73.
15. Wareham DW, Bean DC, Khanna P, Hennessy EM, Krahe D, Ely A, Millar M. Bloodstream infection due to Acinetobacter spp: epidemiology, risk factors and impact of multi-drug resistance. Eur J Clin Microbiol Infect Dis 2008; 27: 607-12.
16. Erbay A, Idil A, Gözel MG, Mumcuoǧlu I, Balaban N. Impact of early appropriate antimicrobial therapy on survival in Acinetobacter baumannii bloodstream infections. Int J Antimicrob Agents 2009; 34: 575-9.
17. Kwon KT, Oh WS, Song JH, Chang HH, Jung SI, Kim SW, Ryu SY, Heo ST, Jung DS, Rhee JY, Shin SY, Ko KS, Peck KR, Lee NY. Impact of imipenem resistance on mortality in patients with Acinetobacter bacteraemia. J Antimicrob Chemother 2007; 59: 525-30.
18. Routsi C, Pratikaki M, Platsouka E, Sotiropoulou C, Nanas S, Markaki V, Vrettou C, Paniara O, Giamarellou H, Roussos C. Carbapenem-resistant versus carbapenem-susceptible Acinetobacter baumannii bacteremia in a Greek intensive care unit: risk factors, clinical features and outcomes. Infection 2010; 38: 173-80.
19. Munoz-Price LS, Zembower T, Penugonda S, Schreckenberger P, Lavin MA, Welbel S, Vais D, Baig M, Mohapatra S, Quinn JP, Weinstein RA. Clinical outcomes of carbapenem-resistant Acinetobacter baumannii bloodstream infections: study of a 2-state monoclonal outbreak. Infect Control Hosp Epidemiol 2010; 31: 1057-62.
20. Choi JY, Park YS, Kim CO, Yoon HJ, Shin SY, Kim YA, Song YG, Yong D, Lee K, Kim JM. Mortality risk factors of Acinetobacter baumannii bacteraemia. Intern Med J 2005; 35: 599-603.
21. Metan G, Sariguzel F, Sumerkan B. Factors influencing survival in patients with multi-drug-resistant Acinetobacter bacteraemia. Eur J Intern Med 2009; 20: 540-4.
22. Krcmery V, Kalavsky E. Multidrug-resistant Acinetobacter baumannii. Emerg Infect Dis 2007; 13: 943-4.
23. Murray CK, Hospenthal DR. Treatment of multidrug resistant Acinetobacter. Curr Opin Infect Dis 2005; 18: 502-6.
24. Cisneros JM, Rodríguez-Baño J. Nosocomial bacteremia due to Acinetobacter baumannii: epidemiology, clinical features and treatment. Clin Microbiol Infect 2002; 8: 687-93.
25. Blot S, Vandewoude K, Colardyn F. Nosocomial bacteremia involving Acinetobacter baumannii in critically ill patients: a matched cohort study. Intensive Care Med 2003; 29: 471-5.
26. Abbo A, Carmeli Y, Navon-Venezia S, Siegman-Igra Y, Schwaber MJ. Impact of multi-drug-resistant Acinetobacter baumannii on clinical outcomes. Eur J Clin Microbiol Infect Dis 2007; 26: 793-800.
27. Montero A, Ariza J, Corbella X, Doménech A, Cabellos C, Ayats J, Tubau F, Ardanuy C, Gudiol F. Efficacy of colistin versus beta-lactams, aminoglycosides, and rifampin as monotherapy in a mouse model of pneumonia caused by multiresistant Acinetobacter baumannii. Antimicrob Agents Chemother 2002; 46: 1946-52.
28. Rodríguez-Hernández MJ, Jiménez-Mejias ME, Pichardo C, Cuberos L, García-Curiel A, Pachón J. Colistin efficacy in an experimental model of Acinetobacter baumannii endocarditis. Clin Microbiol Infect 2004; 10: 581-4.
29. Koomanachai P, Tiengrim S, Kiratisin P, Thamlikitkul V. Efficacy and safety of colistin (colistimethate sodium) for therapy of infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii in Siriraj Hospital, Bangkok, Thailand. Int J Infect Dis 2007; 11: 402-6.
30. Tseng YC, Wang JT, Wu FL, Chen YC, Chie WC, Chang SC. Prognosis of adult patients with bacteremia caused by extensively resistant Acinetobacter baumannii. Diagn Microbiol Infect Dis 2007; 59: 181-90.